STAT3 and medulloblastoma: Pazopanib and Sorafenib also target VEGFR1‐3, PDGFR α/β and c‐kit among other kinases and affect medulloblastoma proliferation and cell survival by inhibition of STAT3 and, to a lesser extend, AKT phosphorylation 22, 39, 40.